JP2025521231A - Cd73抗体カクテル療法 - Google Patents

Cd73抗体カクテル療法 Download PDF

Info

Publication number
JP2025521231A
JP2025521231A JP2024572421A JP2024572421A JP2025521231A JP 2025521231 A JP2025521231 A JP 2025521231A JP 2024572421 A JP2024572421 A JP 2024572421A JP 2024572421 A JP2024572421 A JP 2024572421A JP 2025521231 A JP2025521231 A JP 2025521231A
Authority
JP
Japan
Prior art keywords
binding protein
antigen binding
pharmaceutical composition
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024572421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025521231A5 (cg-RX-API-DMAC10.html
Inventor
シェイ、ジンゲン
ジア、フイフェン
ジャン、イーファン
パン、シャンフェイ
ユウ、ハイジア
ワン、シャオジエ
ザイヤ、シーミン
チュー、シアンヤン
Original Assignee
シャンハイ フアオタ バイオファーマシューティカル カンパニー、リミテッド
フアボ バイオファーム (シャンハイ) カンパニー、リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ フアオタ バイオファーマシューティカル カンパニー、リミテッド, フアボ バイオファーム (シャンハイ) カンパニー、リミテッド filed Critical シャンハイ フアオタ バイオファーマシューティカル カンパニー、リミテッド
Publication of JP2025521231A publication Critical patent/JP2025521231A/ja
Publication of JP2025521231A5 publication Critical patent/JP2025521231A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2024572421A 2022-06-08 2023-06-07 Cd73抗体カクテル療法 Pending JP2025521231A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210639331.4 2022-06-08
CN202210639331 2022-06-08
PCT/CN2023/098753 WO2023236971A1 (zh) 2022-06-08 2023-06-07 Cd73抗体鸡尾酒疗法

Publications (2)

Publication Number Publication Date
JP2025521231A true JP2025521231A (ja) 2025-07-08
JP2025521231A5 JP2025521231A5 (cg-RX-API-DMAC10.html) 2026-05-20

Family

ID=89117604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024572421A Pending JP2025521231A (ja) 2022-06-08 2023-06-07 Cd73抗体カクテル療法

Country Status (8)

Country Link
US (1) US20260217849A1 (cg-RX-API-DMAC10.html)
EP (1) EP4538289A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025521231A (cg-RX-API-DMAC10.html)
KR (1) KR20250023471A (cg-RX-API-DMAC10.html)
CN (1) CN119403832A (cg-RX-API-DMAC10.html)
CA (1) CA3258260A1 (cg-RX-API-DMAC10.html)
TW (1) TW202405018A (cg-RX-API-DMAC10.html)
WO (1) WO2023236971A1 (cg-RX-API-DMAC10.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2017118613A1 (en) * 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
AU2017228470A1 (en) * 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
EP4058150A2 (en) * 2019-11-15 2022-09-21 Genzyme Corporation Biparatopic cd73 antibodies
JP2023546743A (ja) * 2020-10-23 2023-11-07 中山康方生物医▲藥▼有限公司 抗cd73抗体及びその使用
TWI900705B (zh) * 2020-12-11 2025-10-11 大陸商上海華奧泰生物藥業股份有限公司 Cd73的抗原結合蛋白及其應用
US20240067747A1 (en) * 2021-01-13 2024-02-29 Shanghai Huaota Biopharmaceutical Co., Ltd. Cd73-binding protein and use thereof

Also Published As

Publication number Publication date
US20260217849A1 (en) 2026-07-30
CA3258260A1 (en) 2025-03-18
TW202405018A (zh) 2024-02-01
WO2023236971A1 (zh) 2023-12-14
EP4538289A1 (en) 2025-04-16
EP4538289A4 (en) 2026-06-17
KR20250023471A (ko) 2025-02-18
CN119403832A (zh) 2025-02-07

Similar Documents

Publication Publication Date Title
JP2022514693A (ja) Muc18に特異的な抗体
EP4477670A1 (en) Bispecific antigen-binding molecule and use thereof
CN112218895A (zh) 用于癌症治疗的axl特异性抗体
JP2022521624A (ja) 抗cd47抗体を含む製剤、その調製方法および使用
KR20070009637A (ko) 암 세포 증식을 억제하는 항α5β1 항체의 용도
TW202126684A (zh) 抗α-溶血素的抗體及其應用
US9587034B2 (en) Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains
JP2022514786A (ja) Muc18に特異的な抗体
CN119487079A (zh) 一种pvrig/tigit双特异性抗体药物组合物及其用途
CN116323657B (zh) 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
WO2022068894A1 (zh) 同时靶向pd-l1和vegf的双功能分子及其医药用途
CN112839961B (zh) 一种cd40抗体药物组合物及其用途
EP4663202A1 (en) Pharmaceutical preparation containing anti-vegfa and anti-vegfc bispecific binding protein
EP4538289A1 (en) Cd73 antibody cocktail therapy
CN118576543A (zh) 一种结合人CD3/IL13Rα的双特异性抗体制剂及其应用
EA053234B1 (ru) Терапия коктейлем антител против cd73
JP2024530978A (ja) 融合タンパク質を含む医薬組成物
CN116725961A (zh) 抗cd39抗体药物组合物及其用途
TW202313105A (zh) 與貝伐單抗的抗葉酸受體結合物組合療法
US20250297005A1 (en) Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof
CN116688115B (zh) 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途
US20240124576A1 (en) Preparation of siglec-15 binding protein and use thereof
CN121154535A (zh) 一种多特异性抗体药物组合物、其制备方法及其用途
KR20250024056A (ko) 고도로 농축된 항체 조성물
TW202528350A (zh) 抗dr5和ceacam5的雙特異性抗體及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260512